Conclusions This study documents that there exists a statistically significant association between immunoexpression of RUNX2 and grade of tumor, muscle invasion, advanced stage, and lymph node metastasis in urinary bladder cancers, which can guide further management and treatment and can be utilized in the near future for the development of targeted therapy for urinary bladder cancer patients. The gene discussed is RUNX2; the disease is metastatic malignant neoplasm in the lymph nodes.